DK176140B1 - Flagermusspyt-plasminogenaktivatorer - Google Patents

Flagermusspyt-plasminogenaktivatorer Download PDF

Info

Publication number
DK176140B1
DK176140B1 DK198903575A DK357589A DK176140B1 DK 176140 B1 DK176140 B1 DK 176140B1 DK 198903575 A DK198903575 A DK 198903575A DK 357589 A DK357589 A DK 357589A DK 176140 B1 DK176140 B1 DK 176140B1
Authority
DK
Denmark
Prior art keywords
gly
ser
leu
thr
cys
Prior art date
Application number
DK198903575A
Other languages
Danish (da)
English (en)
Other versions
DK357589A (da
DK357589D0 (da
Inventor
Paul A Friedman
George E Mark
Le Thi Duong
Stephen J Gardell
John W Jacobs
Richard A F Dixon
Bruce L Daugherty
Original Assignee
Schering Ag Patentabteilung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag Patentabteilung filed Critical Schering Ag Patentabteilung
Publication of DK357589D0 publication Critical patent/DK357589D0/da
Publication of DK357589A publication Critical patent/DK357589A/da
Application granted granted Critical
Publication of DK176140B1 publication Critical patent/DK176140B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK198903575A 1988-07-20 1989-07-19 Flagermusspyt-plasminogenaktivatorer DK176140B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22169788A 1988-07-20 1988-07-20
US22169788 1988-07-20
US37722189A 1989-07-13 1989-07-13
US37722189 1989-07-13

Publications (3)

Publication Number Publication Date
DK357589D0 DK357589D0 (da) 1989-07-19
DK357589A DK357589A (da) 1990-01-23
DK176140B1 true DK176140B1 (da) 2006-09-25

Family

ID=26916041

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198903575A DK176140B1 (da) 1988-07-20 1989-07-19 Flagermusspyt-plasminogenaktivatorer

Country Status (17)

Country Link
US (1) US5830849A (de)
EP (1) EP0352119B1 (de)
JP (1) JP2713467B2 (de)
KR (1) KR0138997B1 (de)
AT (1) ATE126269T1 (de)
AU (1) AU621389B2 (de)
CA (1) CA1341090C (de)
DE (1) DE68923741T2 (de)
DK (1) DK176140B1 (de)
ES (1) ES2076965T3 (de)
FI (1) FI100403B (de)
GR (1) GR3017587T3 (de)
IE (1) IE69054B1 (de)
IL (1) IL91059A (de)
NO (2) NO302954B1 (de)
NZ (1) NZ230017A (de)
PT (1) PT91236B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01500322A (ja) * 1986-03-28 1989-02-09 クリエイティブ バイオモレクレス,インコーポレーテッド 組織プラスミノーゲンアクテイベーター類縁蛋白質
EP0383417B1 (de) * 1989-02-13 1995-12-27 Schering Aktiengesellschaft Fledermausspeichel-Plasminogenaktivator vPA-alpha 1
US6008019A (en) * 1989-02-13 1999-12-28 Schering Aktiengesellschaft Plasminogen activator from saliva of the vampire bat
DE3943241A1 (de) * 1989-12-22 1991-06-27 Schering Ag Thrombolytisch wirkendes kombinationspraeparat
EP0455424A3 (en) 1990-05-02 1992-04-29 Merck & Co. Inc. Mammalian inducible promoter cascade system
DK0580685T3 (da) * 1991-04-16 1996-03-04 Boehringer Mannheim Gmbh Farmaceutisk emballageenhed indeholdende plasminogenaktivatorer til flerfoldig bolusindgift
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
US5945432A (en) * 1995-12-22 1999-08-31 The University Of Vermont And State Agricultural College Thrombolytic agents and thienopyridine derivatives in acute stroke
US5731186A (en) * 1996-02-05 1998-03-24 Schering Aktiengesellschaft Method for the production of rDSPA α1
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US20060135425A1 (en) * 2003-05-02 2006-06-22 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
BRPI0409865A (pt) * 2003-05-02 2006-05-16 Paion Deutschland Gmbh injeção intravenosa de ativadores de plasminogênio não neurotóxicos para o tratamento do ataque de apoplexia
AU2003227721A1 (en) * 2003-05-02 2004-11-23 Paion Gmbh Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke
DE10342518A1 (de) * 2003-09-12 2005-05-12 Paion Gmbh Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
AR068914A1 (es) * 2007-10-18 2009-12-16 Paion Deutschland Gmbh Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejia
EP2289542A1 (de) 2009-08-31 2011-03-02 PAION Deutschland GmbH Behandlung von neurologischen und neurodegenerativen Erkrankungen
EP2289541A1 (de) 2009-08-31 2011-03-02 PAION Deutschland GmbH Behandlung von neurologischen und neurodegenerativen Erkrankungen
JP7360945B2 (ja) 2017-02-03 2023-10-13 アクティコー バイオテック 抗ヒトgpvi抗体を用いた血小板凝集の阻害
WO2018210860A1 (en) 2017-05-16 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute ischemic stroke
US12123000B2 (en) 2018-06-15 2024-10-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of PI3KC2B inhibitors for the preservation of vascular endothelial cell barrier integrity
MY209917A (en) * 2019-02-05 2025-08-12 Dyno Nobel Asia Pacific Pty Ltd Phase-stabilized ammonium nitrate prills and related products and methods
WO2021148439A1 (en) 2020-01-21 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stimulating cerebrovascular function
EP4161579A1 (de) 2020-06-09 2023-04-12 Institut National de la Santé et de la Recherche Médicale (INSERM) Fucoidanfunktionalisierte polysaccharidpartikel mit t-pa zur gezielten thrombolytischen therapie
EP4482863A1 (de) 2022-02-21 2025-01-01 Acticor Biotech Behandlung von herz-kreislauf-erkrankungen mit anti-humanen gpvi-antikörpern
EP4556492A1 (de) 2023-11-14 2025-05-21 Acticor Biotech Behandlung von herz-kreislauf-erkrankungen mit anti-humanen gpvi-antikörpern in subpopulationen von personen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US5010002A (en) * 1983-01-19 1991-04-23 Genentech, Inc. Human t-PA production using vectors coding DHFR protein
WO1987005934A1 (en) * 1986-03-28 1987-10-08 Roberto Crea Protein analogues of tissue plasminogen activator
ZA887556B (en) * 1987-10-09 1989-07-26 Monsanto Co Modified tissue plasminogen activator
EP0383417B1 (de) * 1989-02-13 1995-12-27 Schering Aktiengesellschaft Fledermausspeichel-Plasminogenaktivator vPA-alpha 1

Also Published As

Publication number Publication date
FI893500L (fi) 1990-01-21
EP0352119A3 (en) 1990-07-04
PT91236B (pt) 1995-03-01
NZ230017A (en) 1992-05-26
AU621389B2 (en) 1992-03-12
DE68923741T2 (de) 1996-02-15
AU3891589A (en) 1990-01-25
CA1341090C (en) 2000-08-29
IE892354L (en) 1990-01-20
KR910003094A (ko) 1991-02-26
ATE126269T1 (de) 1995-08-15
DK357589A (da) 1990-01-23
IE69054B1 (en) 1996-08-07
NO970603L (no) 1990-01-22
NO892976D0 (no) 1989-07-20
FI100403B (fi) 1997-11-28
NO314548B1 (no) 2003-04-07
PT91236A (pt) 1990-02-08
ES2076965T3 (es) 1995-11-16
EP0352119A2 (de) 1990-01-24
US5830849A (en) 1998-11-03
IL91059A0 (en) 1990-02-09
NO302954B1 (no) 1998-05-11
NO892976L (no) 1990-01-22
EP0352119B1 (de) 1995-08-09
KR0138997B1 (ko) 1998-04-30
NO970603D0 (no) 1997-02-10
DK357589D0 (da) 1989-07-19
DE68923741D1 (de) 1995-09-14
GR3017587T3 (en) 1995-12-31
FI893500A0 (fi) 1989-07-19
JPH02167075A (ja) 1990-06-27
IL91059A (en) 1995-06-29
JP2713467B2 (ja) 1998-02-16

Similar Documents

Publication Publication Date Title
FI100403B (fi) Menetelmä glykosyloitujen tai glykosyloimattomien vampyyrilepakon sylj en plasminogeeniaktivaattoreiden valmistamiseksi
FI105202B (fi) Menetelmä aktivoitavien fibrinolyyttisten ja veren hyytymistä estävien plasminogeenianalogien valmistamiseksi
JP4163517B2 (ja) フォンビルブラント因子(vWF)切断酵素
EP0771211A4 (de) Präparate und verfahren zur arzneistoffverabreichung durch blutplättchen zur behandlung von kardiovaskulären erkrankungen
JPH05508150A (ja) 酸化抵抗性トロンボモジュリン類縁体
JPH10513062A (ja) 細胞質アンチプロテイナーゼ−2及び細胞質アンチプロテイナーゼ−3並びにコーディング配列
NO314848B1 (no) Protein for inhibering av kollagenfremkalt blodplateaggregering, DNA som koder for proteinet, vektor som omfatter et slikt DNA, vertscelletransformert medvektoren, fremgangsmåter for fremstilling og rensing avproteinet, farmasöytiskpreparat
NO308708B1 (no) FremgangsmÕte for fremstilling av et trombolytisk protein, samt isolert DNA, mikroorganisme og fremgangsmÕte for fremstilling av et farmasøytisk preparat
RU2143490C1 (ru) Бифункциональный вариант урокиназы, плазмида, содержащая синтетический структурный ген, кодирующий бифункциональную урокиназу, плазмида (варианты), способ получения плазмиды, способ получения бифункционального варианта урокиназы, тромболитическое средство
JPH08511157A (ja) Xaファクター阻害活性を有する新規ポリペプチド
NZ229691A (en) A t-pa analogue with at least one amino acid of native t-pa substituted for another between position 67 and 72
DK175369B1 (da) Anvendelse af tPA-varianter til fremstilling af et terapeutisk præparat til behandling af vaskulæresygdomme
EP0395375B1 (de) Für Ancrod-ähnliche Polypeptide kodierende DNA-Sequenzen und deren Expressionsprodukte enthaltende Zusammensetzungen
CA1341318C (en) Dna clones of human placental plasminogen activator inhibitor
JPH08231595A (ja) 繊維素溶解性のトロンビン阻害性質を有するキメラたん白質
US5801017A (en) Production of recombinant factor Xa inhibitor of leech Hirudo medicinalis
CA2083286C (en) Recombinant fibrinogenases, preparation and use thereof
EP0712934A2 (de) Proteine mit fibrinolytischen und gerinnungshemmenden Eigenschaften
FI100406B (fi) Menetelmä vampyyrilepakon syljen plasminogeeniaktivaattoreiden valmist amiseksi
HU211335A9 (en) New polipeptide compounds
HK1010111A (en) Chimera proteins with fibrinolytic and coagulation inhibiting characteristics

Legal Events

Date Code Title Description
PUP Patent expired